Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Lantern Pharma Inc. (LTRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights"
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 ARS Form ARS - Annual Report to Security Holders:
03/20/2023 10-K Annual Report for the period ended December 31, 2022
03/20/2023 8-K Quarterly results
01/18/2023 8-K Quarterly results
11/21/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights &#9679"
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/03/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/03/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/03/2022 8-K Quarterly results
04/27/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Important Additional Information and Where to Find It"
04/25/2022 8-K Other Events  Interactive Data
03/22/2022 SC 13D/A Bios Equity Partners, LP reports a 18.1% stake in Lantern Pharma Inc.
03/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lantern Pharma Announces Extension of Existing Share Repurchase Program DALLAS, March 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. , a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern’ s existing share repurchase program to acquire up to $7 million of the Company’ s common stock. Since the initiation of the share repurchase program in November 2021, a total of 475,157 shares of common stock have been repurchased pursuant to Lantern’ s share repurchase program. Total expenditures for share repurchases from the time of initiation of..."
03/10/2022 10-K Annual Report for the period ended December 31, 2021
03/10/2022 8-K Investor presentation
Docs: "Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights",
"NASDAQ:LTRN NEW CANCER CATEGORIES RADR"
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR CONTACT:"
01/11/2022 SC 13G/A Empery Asset Management, LP reports a 0% stake in Lantern Pharma Inc.
11/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "www.lanternpharma.com"
11/01/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/01/2021 8-K Investor presentation, Quarterly results
Docs: "November 1st , 2021 4:30 PM Eastern Third quarter 2021 Operating & Financial Results Conference Call / Webinar TODAY’ S SPEAKERS Panna Sharma Chief Financial Officer and Secretary Chief Scientific Officer Finance and A d m inis t r a t i o n Chief Executive Officer, President and Director David Margrave Dr. Kishor Bhatia Nicole Leber NASDAQ:LTRN 1",
"Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights"
07/29/2021 10-Q Quarterly Report for the period ended June 30, 2021
07/29/2021 8-K Investor presentation, Quarterly results
Docs: "Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights",
"Presentation relating to July 29, 2021 conference call and live webcast to discuss financial and operating results for quarter ended June 30, 2021"
07/13/2021 EFFECT Form EFFECT - Notice of Effectiveness:
05/25/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy